Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy.
Summary of "Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy."
Background:â€‚ The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior ischaemic optic neuropathy. Methods:â€‚ Four eyes of four patients comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. Results:â€‚ Mean time between visual loss and the intravitreal injection was 7.8â€ƒdays (range, 2-15â€ƒdays). The mean age of patients was 58.2â€ƒyears (range, 45-63â€ƒyears). After a single dose of ranibizumab injection, all patients experienced a visual gain. Mean visual acuity (VA) was 1.15 Â± 0.26 logMar before the injection and improved to 0.37 Â± 0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. Conclusion:â€‚ Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior ischaemic optic neuropathy and a short disease history.
Dokuz Eylul University, Department of Ophthalmology, Izmir, Turkey E-mail: firstname.lastname@example.org.
This article was published in the following journal.
Name: Clinical & experimental optometry : journal of the Australian Optometrical Association
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21255078
- DOI: http://dx.doi.org/10.1111/j.1444-0938.2010.00570.x
To investigate the relationship between the choroidal thicknesses of eyes of patients with age-related macular degeneration (AMD) and the outcomes of intravitreal ranibizumab injection.
Abstract Purpose: To evaluate corneal and conjunctival sensitivity changes following intravitreal ranibizumab (IVR) injection in eyes with diabetic retinopathy. Methods: Forty-six eyes of 46 patients ...
Abstract Purpose: To present effectiveness of intravitreal ranibizumab (IVR) injection for central serous chorioretinopathy (CSC), resistant to intravitreal bevacizumab (IVB) injection. Methods: Files...
A 67-year-old male who presented to the eye casualty department with deterioration in his vision was diagnosed with retinal angiomatous proliferation. After initial deterioration with ranibizumab intr...
To report a case of marginal keratitis that developed after intravitreal ranibizumab injection.
To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic r...
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eye...
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received ei...
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasm...
The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser co...
Medical and Biotech [MESH] Definitions
Hemorrhagic necrosis that was first demonstrated in rabbits with a two-step reaction, an initial local (intradermal) or general (intravenous) injection of a priming endotoxin (ENDOTOXINS) followed by a second intravenous endotoxin injection (provoking agent) 24 h later. The acute inflammation damages the small blood vessels. The following intravascular coagulation leads to capillary and venous THROMBOSIS and NECROSIS. Shwartzman phenomenon can also occur in other species with a single injection of a provoking agent, and during infections or pregnancy. Its susceptibility depends on the status of IMMUNE SYSTEM, coagulation, FIBRINOLYSIS, and blood flow.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
Acute conjunctival inflammation in the newborn, usually caused by maternal gonococcal infection. The causative agent is NEISSERIA GONORRHOEAE. The baby's eyes are contaminated during passage through the birth canal.
Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes.
Partial or complete loss of vision in one half of the visual field(s) of one or both eyes. Subtypes include altitudinal hemianopsia, characterized by a visual defect above or below the horizontal meridian of the visual field. Homonymous hemianopsia refers to a visual defect that affects both eyes equally, and occurs either to the left or right of the midline of the visual field. Binasal hemianopsia consists of loss of vision in the nasal hemifields of both eyes. Bitemporal hemianopsia is the bilateral loss of vision in the temporal fields. Quadrantanopsia refers to loss of vision in one quarter of the visual field in one or both eyes.